A detailed history of Ubs Group Ag transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 2,236 shares of RNXT stock, worth $2,817. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,236
Previous 1,305 71.34%
Holding current value
$2,817
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.96 - $1.29 $893 - $1,200
931 Added 71.34%
2,236 $2,000
Q2 2024

Aug 13, 2024

BUY
$1.02 - $1.46 $1,331 - $1,905
1,305 New
1,305 $1,000
Q1 2023

May 12, 2023

BUY
$2.51 - $5.25 $6,350 - $13,282
2,530 New
2,530 $8,000
Q3 2022

Nov 10, 2022

SELL
$1.84 - $2.79 $9,128 - $13,841
-4,961 Reduced 79.8%
1,256 $3,000
Q2 2022

Aug 10, 2022

BUY
$1.52 - $2.99 $9,449 - $18,588
6,217 New
6,217 $12,000
Q1 2022

May 16, 2022

SELL
$2.87 - $4.9 $12,949 - $22,108
-4,512 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.72 - $8.5 $21,296 - $38,352
4,512 New
4,512 $22,000

Others Institutions Holding RNXT

About RenovoRx, Inc.


  • Ticker RNXT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,066,860
  • Market Cap $11.4M
  • Description
  • RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...
More about RNXT
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.